Does the media refer more to CMPS or CCCC?

In the previous week, Compass Pathways had 5 more articles in the media than C4 Therapeutics. MarketBeat recorded 7 mentions for Compass Pathways and 2 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 1.87 beat Compass Pathways' score of 0.84 indicating that C4 Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Pathways 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive C4 Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to NTLA or CCCC?

In the previous week, Intellia Therapeutics had 1 more articles in the media than C4 Therapeutics. MarketBeat recorded 3 mentions for Intellia Therapeutics and 2 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 1.87 beat Intellia Therapeutics' score of 1.11 indicating that C4 Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive C4 Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer MPLT or CCCC?

In the previous week, Maplight Therapeutics had 1 more articles in the media than C4 Therapeutics. MarketBeat recorded 3 mentions for Maplight Therapeutics and 2 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 1.87 beat Maplight Therapeutics' score of 1.49 indicating that C4 Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maplight Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive C4 Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor CCCC or MAZE?

In the previous week, Maze Therapeutics had 2 more articles in the media than C4 Therapeutics. MarketBeat recorded 4 mentions for Maze Therapeutics and 2 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 1.87 beat Maze Therapeutics' score of 1.24 indicating that C4 Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment C4 Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Maze Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CCCC or VIR?

In the previous week, Vir Biotechnology had 4 more articles in the media than C4 Therapeutics. MarketBeat recorded 6 mentions for Vir Biotechnology and 2 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 1.87 beat Vir Biotechnology's score of 0.75 indicating that C4 Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment C4 Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Vir Biotechnology 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

C4 Therapeutics (CCCC) Competitors

$3.40 -0.25 (-6.85%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$3.43 +0.03 (+0.88%)

As of 07/24/2026 07:34 PM Eastern

Compare

CCCC vs. CMPS, NTLA, MPLT, MAZE, and VIR

Should you buy C4 Therapeutics stock or one of its competitors? MarketBeat compares C4 Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with C4 Therapeutics include Compass Pathways (CMPS), Intellia Therapeutics (NTLA), Maplight Therapeutics (MPLT), Maze Therapeutics (MAZE), and Vir Biotechnology (VIR). These companies are all part of the "pharmaceutical products" industry.

How does C4 Therapeutics compare to Compass Pathways?

Compass Pathways (NASDAQ:CMPS) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

46.2% of Compass Pathways shares are held by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are held by institutional investors. 2.8% of Compass Pathways shares are held by company insiders. Comparatively, 5.6% of C4 Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Compass Pathways has a net margin of 0.00% compared to C4 Therapeutics' net margin of -297.76%. Compass Pathways' return on equity of -31.07% beat C4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Pathways	N/A	-31.07%	-11.40%
C4 Therapeutics	-297.76%	-50.68%	-33.22%

Compass Pathways presently has a consensus price target of $24.15, indicating a potential upside of 114.51%. C4 Therapeutics has a consensus price target of $7.75, indicating a potential upside of 127.94%. Given C4 Therapeutics' higher possible upside, analysts clearly believe C4 Therapeutics is more favorable than Compass Pathways.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Pathways	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94
C4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

C4 Therapeutics has higher revenue and earnings than Compass Pathways. Compass Pathways is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Pathways	N/A	N/A	-$287.86M	-$3.15	N/A
C4 Therapeutics	$34.86M	10.78	-$104.99M	-$1.19	N/A

In the previous week, Compass Pathways had 5 more articles in the media than C4 Therapeutics. MarketBeat recorded 7 mentions for Compass Pathways and 2 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 1.87 beat Compass Pathways' score of 0.84 indicating that C4 Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Pathways	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
C4 Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Compass Pathways has a beta of 2.47, meaning that its stock price is 147% more volatile than the broader market. Comparatively, C4 Therapeutics has a beta of 2.9, meaning that its stock price is 190% more volatile than the broader market.

Summary

C4 Therapeutics beats Compass Pathways on 9 of the 16 factors compared between the two stocks.

How does C4 Therapeutics compare to Intellia Therapeutics?

Intellia Therapeutics (NASDAQ:NTLA) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and media sentiment.

Intellia Therapeutics has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market. Comparatively, C4 Therapeutics has a beta of 2.9, indicating that its stock price is 190% more volatile than the broader market.

Intellia Therapeutics currently has a consensus price target of $20.19, suggesting a potential upside of 88.14%. C4 Therapeutics has a consensus price target of $7.75, suggesting a potential upside of 127.94%. Given C4 Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe C4 Therapeutics is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	4 Sell rating(s)	9 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.30
C4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Intellia Therapeutics had 1 more articles in the media than C4 Therapeutics. MarketBeat recorded 3 mentions for Intellia Therapeutics and 2 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 1.87 beat Intellia Therapeutics' score of 1.11 indicating that C4 Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intellia Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
C4 Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

C4 Therapeutics has lower revenue, but higher earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$67.67M	22.15	-$412.69M	-$3.54	N/A
C4 Therapeutics	$34.86M	10.78	-$104.99M	-$1.19	N/A

88.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are held by institutional investors. 3.5% of Intellia Therapeutics shares are held by insiders. Comparatively, 5.6% of C4 Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

C4 Therapeutics has a net margin of -297.76% compared to Intellia Therapeutics' net margin of -597.04%. C4 Therapeutics' return on equity of -50.68% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-597.04%	-57.47%	-46.24%
C4 Therapeutics	-297.76%	-50.68%	-33.22%

Summary

C4 Therapeutics beats Intellia Therapeutics on 11 of the 17 factors compared between the two stocks.

How does C4 Therapeutics compare to Maplight Therapeutics?

Maplight Therapeutics (NASDAQ:MPLT) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

Maplight Therapeutics has a net margin of 0.00% compared to C4 Therapeutics' net margin of -297.76%. Maplight Therapeutics' return on equity of 0.00% beat C4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	N/A	N/A
C4 Therapeutics	-297.76%	-50.68%	-33.22%

C4 Therapeutics has higher revenue and earnings than Maplight Therapeutics. C4 Therapeutics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A
C4 Therapeutics	$34.86M	10.78	-$104.99M	-$1.19	N/A

Maplight Therapeutics presently has a consensus price target of $40.82, suggesting a potential upside of 11.65%. C4 Therapeutics has a consensus price target of $7.75, suggesting a potential upside of 127.94%. Given C4 Therapeutics' higher probable upside, analysts clearly believe C4 Therapeutics is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	5 Strong Buy rating(s)	3.12
C4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Maplight Therapeutics had 1 more articles in the media than C4 Therapeutics. MarketBeat recorded 3 mentions for Maplight Therapeutics and 2 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 1.87 beat Maplight Therapeutics' score of 1.49 indicating that C4 Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maplight Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
C4 Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

78.8% of C4 Therapeutics shares are owned by institutional investors. 3.8% of Maplight Therapeutics shares are owned by company insiders. Comparatively, 5.6% of C4 Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Maplight Therapeutics beats C4 Therapeutics on 8 of the 15 factors compared between the two stocks.

How does C4 Therapeutics compare to Maze Therapeutics?

C4 Therapeutics (NASDAQ:CCCC) and Maze Therapeutics (NASDAQ:MAZE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership.

C4 Therapeutics has a beta of 2.9, meaning that its stock price is 190% more volatile than the broader market. Comparatively, Maze Therapeutics has a beta of 2.14, meaning that its stock price is 114% more volatile than the broader market.

Maze Therapeutics has a net margin of 0.00% compared to C4 Therapeutics' net margin of -297.76%. Maze Therapeutics' return on equity of -36.62% beat C4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
C4 Therapeutics	-297.76%	-50.68%	-33.22%
Maze Therapeutics	N/A	-36.62%	-31.78%

78.8% of C4 Therapeutics shares are owned by institutional investors. 5.6% of C4 Therapeutics shares are owned by company insiders. Comparatively, 5.3% of Maze Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Maze Therapeutics had 2 more articles in the media than C4 Therapeutics. MarketBeat recorded 4 mentions for Maze Therapeutics and 2 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 1.87 beat Maze Therapeutics' score of 1.24 indicating that C4 Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
C4 Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Maze Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

C4 Therapeutics currently has a consensus price target of $7.75, indicating a potential upside of 127.94%. Maze Therapeutics has a consensus price target of $66.00, indicating a potential upside of 138.44%. Given Maze Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Maze Therapeutics is more favorable than C4 Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
C4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

C4 Therapeutics has higher revenue and earnings than Maze Therapeutics. Maze Therapeutics is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
C4 Therapeutics	$34.86M	10.78	-$104.99M	-$1.19	N/A
Maze Therapeutics	$20M	76.60	-$131.12M	-$2.53	N/A

Summary

Maze Therapeutics beats C4 Therapeutics on 9 of the 17 factors compared between the two stocks.

How does C4 Therapeutics compare to Vir Biotechnology?

C4 Therapeutics (NASDAQ:CCCC) and Vir Biotechnology (NASDAQ:VIR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

78.8% of C4 Therapeutics shares are owned by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are owned by institutional investors. 5.6% of C4 Therapeutics shares are owned by company insiders. Comparatively, 2.9% of Vir Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

C4 Therapeutics has a beta of 2.9, indicating that its stock price is 190% more volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.62, indicating that its stock price is 62% more volatile than the broader market.

C4 Therapeutics has higher earnings, but lower revenue than Vir Biotechnology. C4 Therapeutics is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
C4 Therapeutics	$34.86M	10.78	-$104.99M	-$1.19	N/A
Vir Biotechnology	$64.69M	22.66	-$437.99M	-$3.13	N/A

C4 Therapeutics currently has a consensus price target of $7.75, indicating a potential upside of 127.94%. Vir Biotechnology has a consensus price target of $20.88, indicating a potential upside of 140.22%. Given Vir Biotechnology's stronger consensus rating and higher probable upside, analysts plainly believe Vir Biotechnology is more favorable than C4 Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
C4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

C4 Therapeutics has a net margin of -297.76% compared to Vir Biotechnology's net margin of -638.88%. C4 Therapeutics' return on equity of -50.68% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
C4 Therapeutics	-297.76%	-50.68%	-33.22%
Vir Biotechnology	-638.88%	-53.31%	-41.76%

In the previous week, Vir Biotechnology had 4 more articles in the media than C4 Therapeutics. MarketBeat recorded 6 mentions for Vir Biotechnology and 2 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 1.87 beat Vir Biotechnology's score of 0.75 indicating that C4 Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
C4 Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Vir Biotechnology	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

C4 Therapeutics beats Vir Biotechnology on 9 of the 17 factors compared between the two stocks.

Get C4 Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CCCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CCCC vs. The Competition

Export

Metric	C4 Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$403.57M	$3.67B	$6.87B	$12.28B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-2.86	21.29	27.11	23.71
Price / Sales	10.78	161.49	496.35	75.28
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	1.28	7.88	10.28	6.07
Net Income	-$104.99M	$23.86M	$3.60B	$331.99M
7 Day Performance	-7.86%	-3.82%	-1.27%	-0.63%
1 Month Performance	-22.73%	-2.61%	-0.37%	-2.00%
1 Year Performance	50.44%	32.79%	18.30%	13.62%

C4 Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CCCC C4 Therapeutics	2.2567 of 5 stars	$3.40 -6.8%	$7.75 +127.9%	+48.5%	$403.57M	$34.86M	N/A	150	News Coverage
CMPS Compass Pathways	3.1119 of 5 stars	$11.95 +2.4%	$24.15 +102.2%	+157.7%	$1.61B	N/A	N/A	120	News Coverage Positive News Upcoming Earnings
NTLA Intellia Therapeutics	3.6615 of 5 stars	$11.50 +5.3%	$20.19 +75.5%	-16.0%	$1.61B	$67.67M	N/A	600
MPLT Maplight Therapeutics	2.0802 of 5 stars	$37.63 +4.5%	$40.09 +6.6%	N/A	$1.60B	N/A	N/A	109	Positive News Analyst Forecast
MAZE Maze Therapeutics	2.1557 of 5 stars	$29.17 +2.8%	$66.00 +126.3%	+68.3%	$1.60B	$167.50M	N/A	121	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CCCC) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

C4 Therapeutics (CCCC) Competitors

CCCC vs. CMPS, NTLA, MPLT, MAZE, and VIR

How does C4 Therapeutics compare to Compass Pathways?

Summary

How does C4 Therapeutics compare to Intellia Therapeutics?

Summary

How does C4 Therapeutics compare to Maplight Therapeutics?

Summary

How does C4 Therapeutics compare to Maze Therapeutics?

Summary

How does C4 Therapeutics compare to Vir Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CCCC vs. The Competition

C4 Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

C4 Therapeutics (CCCC) Competitors

CCCC vs. CMPS, NTLA, MPLT, MAZE, and VIR

How does C4 Therapeutics compare to Compass Pathways?

Do institutionals & insiders believe in CMPS or CCCC?

Is CMPS or CCCC more profitable?

Do analysts rate CMPS or CCCC?

Which has higher valuation & earnings, CMPS or CCCC?

Does the media refer more to CMPS or CCCC?

Which has more risk & volatility, CMPS or CCCC?

Summary

How does C4 Therapeutics compare to Intellia Therapeutics?

Which has more volatility & risk, NTLA or CCCC?

Do analysts recommend NTLA or CCCC?

Does the media refer more to NTLA or CCCC?

Which has preferable earnings & valuation, NTLA or CCCC?

Do institutionals & insiders hold more shares of NTLA or CCCC?

Is NTLA or CCCC more profitable?

Summary

How does C4 Therapeutics compare to Maplight Therapeutics?

Is MPLT or CCCC more profitable?

Which has better valuation & earnings, MPLT or CCCC?

Do analysts prefer MPLT or CCCC?

Does the media prefer MPLT or CCCC?

Do institutionals and insiders hold more shares of MPLT or CCCC?

Summary

How does C4 Therapeutics compare to Maze Therapeutics?

Which has more risk and volatility, CCCC or MAZE?

Is CCCC or MAZE more profitable?

Do insiders & institutionals have more ownership in CCCC or MAZE?

Does the media favor CCCC or MAZE?

Do analysts prefer CCCC or MAZE?

Which has better valuation and earnings, CCCC or MAZE?

Summary

How does C4 Therapeutics compare to Vir Biotechnology?

Do insiders & institutionals have more ownership in CCCC or VIR?

Which has more volatility and risk, CCCC or VIR?

Which has higher valuation and earnings, CCCC or VIR?

Do analysts recommend CCCC or VIR?

Is CCCC or VIR more profitable?

Does the media favor CCCC or VIR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CCCC vs. The Competition

C4 Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools